Ketoprofen (Oruvail) SR capsules: Discontinuation

Affected product

The supplier, Sanofi, advises that ketoprofen (Oruvail) SR capsules 200mg are being discontinued globally. 

Ketoprofen

Presentation: Capsules SR 200

• Brand: Oruvail 
• Pharmacode: 397148
• Subsidy: $12.07
• Measure / Qty: 200mg 

Key dates

• 31 March 2026: Oruvail SR capsules 200mg estimated to run out 
• 1 April 2026: Estimated delisting from the Pharmaceutical Schedule.

People who take Oruvail capsules 

You will need a new prescription for a different treatment. You will need to talk to the person who prescribes your anti-imflammatory medication before the end of the year. They will work with you to find an effective alternative. 

We appreciate that changing treatments can be disruptive. We apologise for any inconvenience this causes. 

Health care professionals

Pharmacists

We would appreciate it if you could advise anyone picking up Oruvail capsules that they will need to change treatment in early 2025. 

We have developed an A5 flier to support your conversations with people about this discontinuation.

Prescribers of Oruvail capsules

You will need to change your patients from Oruvail to a new treatment.

Clinical advice has confirmed that other fully funded non-steroidal anti-inflammatory drugs (NSAID) are available, such as ibuprofen, tenoxicam and naproxen. 

Schedule listings for non-steroidal anti-inflammatory drugs(external link)

Non-steroidal anti-inflammatory drugs – NZ Formulary(external link)

Thank you

We appreciate the time and effort you give to help people when their medicine has to change.

Who to contact

If you have questions about this issue, email enquiry@pharmac.govt.nz

Please include as much information as you can about the product (presentation, brand, pharmacode) and who your wholesaler is.

Sign up to our email list for regular emails about supply issues and more(external link)